Umang Vohra appointed Executive Chairman and Group CEO of Cohance Lifesciences
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
This transaction fundamentally strengthens Scinai's CDMO platform
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
This strategic investment strengthens Cohance's integrated oligonucleotide platform
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated